Catherine Thieblemont

机构：Délégation Paris 5, Inserm, Université Paris Cité, Saint Louis University Hospital, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre de Recherche Épidémiologie et Statistique, NF-kappaB, Différenciation et Cancer, Martin Luther University Halle-Wittenberg

发表论文 109 篇 · 总被引 2482 次 · h-index 12

代表论文

• Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial (2025 · The Lancet · 被引 20)
• Clinical outcomes of tisagenlecleucel in patients with relapsed/refractory follicular lymphoma (r/r FL): Phase 2 ELARA 5-year update (2025 · Blood · 被引 4)
• ABCL-404: Epcoritamab + R-ICE in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Eligible For Autologous Stem Cell Transplantation (ASCT): EPCORE NHL-2 (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)
• Indirect Comparison of Epcoritamab Versus Axicabtagene Ciloleucel in Chimeric Antigen Receptor T-Cell–Eligible and –Naive Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 3)
• Fixed-duration epcoritamab monotherapy induces high response and MRD-negativity rates in elderly patients with newly diagnosed large B-cell lymphoma (LBCL) and comorbidities: Results from EPCORE DLBCL-3 (2025 · Blood · 被引 2)
• Odronextamab (Odro) plus lenalidomide (+Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL): First results from part 1 (safety lead-in) of the Phase 3 OLYMPIA-5 study (2025 · Blood · 被引 2)